Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;31(1):45-51.
doi: 10.3803/EnM.2016.31.1.45.

In Vivo Models for Incretin Research: From the Intestine to the Whole Body

Affiliations
Review

In Vivo Models for Incretin Research: From the Intestine to the Whole Body

Tae Jung Oh. Endocrinol Metab (Seoul). 2016 Mar.

Abstract

Incretin hormones are produced by enteroendocrine cells (EECs) in the intestine in response to ingested nutrient stimuli. The incretin effect is defined as the difference in the insulin secretory response between the oral glucose tolerance test and an isoglycemic intravenous glucose infusion study. The pathophysiology of the decreased incretin effect has been studied as decreased incretin sensitivity and/or β-cell dysfunction per se. Interestingly, robust increases in endogenous incretin secretion have been observed in many types of metabolic/bariatric surgery. Therefore, metabolic/bariatric surgery has been extensively studied for incretin physiology, not only the hormones themselves but also alterations in EECs distribution and genetic expression levels of gut hormones. These efforts have given us an enormous understanding of incretin biology from synthesis to in vivo behavior. Further innovative studies are needed to determine the mechanisms and targets of incretin hormones.

Keywords: Bariatric surgery; Enteroendocrine cells; Incretins.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance (NGT) or (B) type 2 diabetes mellitus (T2DM). Plasma glucose profiles of oral glucose tolerance test (OGTTs) (filled symbol) and IIGI studies (open symbol) in subjects with (C) NGT or (D) T2DM. Adapted from Oh et al. [21], with permission from John Wiley and Sons.

Similar articles

Cited by

References

    1. Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75–85. - PubMed
    1. Cho YM, Kieffer TJ. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam Horm. 2010;84:111–150. - PubMed
    1. Cho YM, Fujita Y, Kieffer TJ. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol. 2014;76:535–559. - PubMed
    1. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 1995;16:390–410. - PubMed
    1. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl):S3–S18. - PubMed

LinkOut - more resources